Relationship Between Serum N/OFQ and Brain-heart Syndrome

February 17, 2023 updated by: Zheng Guo

Relationship Between Serum N/OFQ and Cerebral Cardiac Syndrome After Stroke

Choosing the neurology patients in the Second Hospital of Shanxi Medical University, diagnosed with patients with cerebral syndrome into the experimental group; patients who did not have cerebral syndrome included in the control group, and all selected people had no intimate relationship with each other.Specimen collecting control group and the study group serum inflammatory factor IL-6, solvent peptide and catecholamine content. The difference between the two groups of data was observed.According to the literature, it is guess: The solitary peptide content of the experimental group will be higher than the control group, and is positively correlated with IL-6, catecholamine content.The difference was statistically significant.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • Recruiting
        • Second of Shanxi Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients in the Second Hospital of Shanxi Medical University from May 2022 to October 2023

Description

Inclusion Criteria:

  • Diagnostic criteria in compliance with cerebral syndrome
  • Acute ischemic stroke patients in line with the "Chinese Acute Ischemic Stroke Treatment Guide 2018" related diagnostic criteria
  • There is no intimate relationship between all selected people and knows this study, and signs informed consent

Exclusion Criteria:

  • Heart-type cerebral infarction, hemorrhagic stroke, brain tumor and past intracranial hemorrhage
  • Complicated with severe cardiovascular complications (such as coronary heart disease, acute coronary syndrome, acute myocardial infarction, chronic heart failure, atrial fibrillation, etc.)
  • Complicated with severe liver and kidney dysfunction (such as coagulous dysfunction, cirrhosis, nephrotic syndrome , Renal failure, etc.)
  • Complicated with severe diabetes complications (such as diabetic nephropathy, diabetic foot, diabetic acidosis, high blood sugar hypertonic state, diabetes coronary heart disease, etc.)
  • Complicated with Psychological disease
  • Complicated with chronic obstructive pulmonary disease(COPD)
  • BMI> 40

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CCS group
Patients with cerebral syndrome diagnosed by the Second Hospital of Shanxi Medical University
Diagnostic test: Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-6 and NE levels were detected.
Control group
Patients who have not had a cerebral syndrome in ischemic stroke
Diagnostic test: Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-6 and NE levels were detected.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
N/OFQ
Time Frame: 24 hours
Serum N/OFQ levels
24 hours
IL-6
Time Frame: 24 hours
Serum IL-6 levels
24 hours
NE
Time Frame: 24 hours
Serum NE levels
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zheng Guo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

May 1, 2023

Primary Completion (Anticipated)

September 30, 2023

Study Completion (Anticipated)

October 31, 2023

Study Registration Dates

First Submitted

April 18, 2022

First Submitted That Met QC Criteria

April 18, 2022

First Posted (Actual)

April 25, 2022

Study Record Updates

Last Update Posted (Estimate)

February 21, 2023

Last Update Submitted That Met QC Criteria

February 17, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • hanyi20220418

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral-Cardiac Syndrome

Clinical Trials on Enzyme-linked immunosorbent assay

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe